Chief Financial Officer · Mirum Pharmaceuticals, Inc. (MIRM)

Ian Clements

A named executive officer of Mirum Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,980,556

Salary $425,000Stock awards $239,906

FY2020: $1,389,494

2nd of 4 named executive officers at Mirum Pharmaceuticals by FY2021 total.

4 named officers on file for Mirum Pharmaceuticals, FY2021

Ian Clements’s pay file — $29

  • 2 fiscal years of pay, line by line
  • MIRM’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mirum Pharmaceuticals’s whole pay program stands against its peers

  • Mirum Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MIRM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2022 (DEF 14A).

Free

Get Ian Clements’s full pay file as a PDF — free

More than this page: up to 10 years of Ian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ian Clements compensation by year

Mirum Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Mirum Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$378,390$425,000
Bonus$0$0
Stock awards$0$239,906
Option awards$848,348$1,091,550
Non-equity incentive$151,356$212,500
Pension and deferred compensation$0$0
All other$11,400$11,600
Total$1,389,494$1,980,556

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirum Pharmaceuticals, Inc. DEF 14A filed April 22, 2022, accession 0001140361-22-015567, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mirum Pharmaceuticals, Inc. filed document, accession 0001140361-22-015567. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2022.

$1.4M
$2.0M
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU4,688$74,774—
Option27,344—$2.94
Option21,875—$6.27
Option33,855—$19.24
Option75,000—$19.19

Per the Outstanding Equity Awards at Fiscal Year-End table in Mirum Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Mirum Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Christopher PeetzPresident and Chief Executive Officer$4,130,831
Ian Clements · this pageChief Financial Officer$1,980,556
Edwin TuckerFormer Chief Medical Officer$1,955,721
Peter RadovichChief Operating Officer$1,803,029

The full Mirum Pharmaceuticals compensation record

free company brief

This page is one person within Mirum Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mirum Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirum Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ian Clements's compensation dossier · One-time report. No refunds.